On May 6, 2025, IceCure Medical Ltd. announced its participation in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting, held from April 30 to May 4, 2025. The company reported a high level of interest in its ProSense® system from breast surgeons, particularly following the recent positive U.S. Food and Drug Administration (FDA) development regarding its pathway to marketing authorization.
Many doctors approached IceCure's booth, expressing interest in participating in the planned post-market study and offering ProSense® to their patients once marketing authorization is granted. Cryoablation for breast cancer was positively mentioned in prominent presentations, including the Presidential Address and the Best Papers of 2024 review, highlighting its growing recognition and potential to offer greater choice to women with early-stage breast cancer.
The ASBrS Presidential Address specifically mentioned the ICE3 study and noted that the ASBrS awaits a final FDA decision for breast cancer cryoablation. This strong engagement from leading breast surgeons underscores the medical community's readiness for minimally invasive alternatives and reinforces the significance of IceCure's ongoing regulatory progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.